JEMINA LIVERMAN: Open Payments
NPI 1073889697 · NEWPORT NEWS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$752 in 25 payments from 7 companies in 2025. Trend: 2023 $1,224 · 2024 $1,099 · 2025 $752
Food & beverage: $752
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $162 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 6 | $116 |
| Neurocrine BioSciences, Inc. | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| ABBVIE INC. | 4 | $82 |
| Janssen Pharmaceuticals, Inc | 2 | $71 |
Products named: CAPLYTA, XIFAXAN, INGREZZA, AUSTEDO XR, VRAYLAR, SPRAVATO, REXULTI, UZEDY.
Industry payments across VA — which companies pay providers there.
